1.
Medicine (Baltimore)
; 96(14): e6275, 2017 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28383402
RESUMO
We determined risk of virologic failure (VF) in individuals initiating tenofovir/emtricitabine/efavirenz as single versus multiple tablet regimens (MTR). We found no significant difference in the risk of VF, though did observe a trend toward more VF and M184âV mutations among persons initiating MTR. Temporal trends in care may have confounded results.